ReviewThe Journal of clinical endocrinology and metabolism2026
Approach to the Patient With Pancreatogenic Diabetes.
Review in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- More Than Stress Hyperglycemia: Acute Pancreatitis as a Prelude to Diabetes.Diabetes care · 2026Article
- The Metabolic Legacy of Acute Pancreatitis: Post-Pancreatitis Diabetes Mellitus.Clinical and experimental gastroenterology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Diabetes can occur secondary to a wide array of exocrine pancreas pathologies. Pancreatogenic diabetes is a broad diagnostic term used to encompass these disparate causes of diabetes, which taken together are estimated to account for 1% to 9% of all cases of diabetes. The more common causes of pancreatogenic diabetes include pancreatitis, pancreatic ductal adenocarcinoma, cystic fibrosis, pancreatectomy, and fibrocalculous pancreatic disease. Persons with these exocrine pancreatic conditions should be screened for diabetes. Reciprocally, clinicians should consider the possibility of underlying pancreatic disease in persons with diabetes. Of special concern, diabetes can be the presenting sign of pancreatic ductal adenocarcinoma, for which clinical suspicion remains crucial as there are not yet distinguishing biomarkers. Timely diagnosis of diabetes is especially important in cystic fibrosis, because even mild diabetes can worsen lung disease and mortality risk in this condition. Exocrine pancreatic insufficiency is present in many cases of pancreatogenic diabetes. In these cases, provision of pancreatic enzyme replacement therapy may improve glycemic control. Optimal screening and treatment approaches are evolving, differing depending on the specific pancreatic pathology. Clinicians should be vigilant for exocrine pancreas symptomatology, including abdominal pain, steatorrhea, and malabsorption in their patients with diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.